Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα

Guilin Ren, Yiyou Lin, Jiannan Qiu, Xiao Han, Lin Chen, Linwensi Zhu, Xiaohui Fan, Xiaobing Dou, Qingsheng LiuFrontiers in Pharmacology 2025 · DOI

This study, published in Frontiers in Pharmacology, explores how Pachymic acid (Pac)—a bioactive compound derived from the medicinal fungus Poria cocos—acts as a multi-target therapeutic for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The researchers demonstrate that Pac alleviates liver damage by activating the metabolic regulator PPARα, which in turn suppresses inflammatory MAPK signaling and prevents ferroptosis (a specific form of iron-dependent cell death).

TL;DR

Pachymic acid effectively reverses fatty liver disease in mice by flipping a metabolic switch (PPARα) that prevents iron-driven cell suicide (ferroptosis). This dual action—improving lipid metabolism while blocking stress-induced cell death—positions Pac as a promising natural candidate for treating MASLD.

What Problem Does This Paper Address?

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as NAFLD, is a global epidemic linked to obesity and insulin resistance. While it begins with simple fat accumulation (steatosis), it can progress to severe inflammation (MASH), cirrhosis, and liver cancer.

A major driver of this progression is ferroptosis, a type of programmed cell death triggered by iron overload and the failure of antioxidant defenses to stop lipid peroxidation (the "rusting" of cell membranes). Current treatments are limited, and there is a high demand for compounds that can simultaneously manage metabolic dysfunction and protect hepatocytes from dying. The authors sought to determine if Pachymic acid, known for its anti-inflammatory properties, could specifically target the PPARα/MAPK axis to halt this process.

Methods

The researchers employed a robust combination of in vivo and in vitro techniques:

  • Animal Model: Male C57BL/6J mice were fed a high-fat diet (HFD) for 8 weeks to induce MASLD, followed by 4 weeks of Pac treatment.
  • Cell Culture: AML-12 (mouse liver) cells were treated with fatty acids (palmitate and oleate) to simulate MASLD conditions in a dish.
  • Mechanism Validation: To prove that PPARα was the "master switch," the team used GW6471, a selective PPARα inhibitor. If Pac's benefits disappeared when PPARα was blocked, it would confirm the pathway.
  • Multi-Omics & Imaging: The study utilized RNA sequencing (transcriptomics) to identify gene expression changes, Western blotting for protein levels, and advanced imaging (Mito-Tracker, Bodipy) to visualize mitochondrial health and fat droplets.

Datasets

The primary dataset generated was the transcriptomic profile of liver samples from three groups: Normal Control (NC), High-Fat Diet (HFD), and HFD + High-dose Pac.

  • The raw sequencing data is deposited in the NCBI BioProject database (PRJNA1157833).
  • The study identified 737 genes with overlapping expression changes across the groups, highlighting the MAPK and PPAR signaling pathways as key targets.

Key Insights and Ideas

  • The PPARα-Ferroptosis Link: The most significant "aha" moment was identifying that PPARα activation directly upregulates GPX4 and SLC7A11. These are the cell’s primary "brakes" for ferroptosis. By boosting these, Pac prevents the liver from "rusting" under metabolic stress.
  • MAPK Suppression: The study clarifies a discrepancy in previous literature. While some reports suggested Pac might increase certain stress signals, this paper shows that in the context of a fatty liver, Pac actually suppresses the phosphorylation of the MAPK family (JNK, p38, and ERK), thereby reducing inflammation and cell death.
  • Multi-Target Efficacy: Pac didn't just fix one thing; it reduced body weight, lowered blood lipids (TG and TC), and restored liver architecture, performing comparably to the positive control drug, polyene phosphatidylcholine (YSF).

Key Results

  • Liver Injury: Pac significantly decreased plasma levels of ALT and AST (key markers of liver damage).
  • Lipid Metabolism: Pac treatment markedly reduced hepatic triglyceride (TG) and total cholesterol (TC) levels.
  • Ferroptosis Markers: Pac lowered levels of malondialdehyde (MDA) and 4-HNE (markers of lipid damage) and reduced the accumulation of ferrous iron (Fe²⁺) in the liver.
  • Protein Expression: Pac treatment led to a significant increase in PPARα and GPX4 protein levels while decreasing the activation (phosphorylation) of the pro-inflammatory ASK1/MAPK pathway.
  • Inhibitor Reversal: When the PPARα inhibitor (GW6471) was introduced, the protective effects of Pac on lipid accumulation and ferroptosis were almost entirely abolished, proving the mechanism.

Limitations and Future Work

  • Species Translation: As with most preclinical research, the study was conducted in mice. Human metabolism and the progression of MASLD are more complex, requiring clinical validation.
  • Bioavailability: The paper does not extensively discuss the pharmacokinetics or bioavailability of Pac when administered orally, which is a common hurdle for triterpenoids.
  • Gut-Liver Axis: Given that Poria cocos is a traditional dietary supplement, future work could explore how Pac interacts with the gut microbiome, which is known to play a massive role in MASLD.
  • Long-term Safety: While 4 weeks of treatment showed benefits, MASLD is a chronic condition requiring long-term management; future studies should look at the safety and efficacy of Pac over extended periods.

Summary updated

Abstract

The study demonstrated that Pac inhibited the MAPKs signaling pathway and reduced hepatic ferroptosis, alleviated steatosis through PPARα regulation, offering a potential therapeutic strategy for MASLD.
BibTeX
@inproceedings{ren2025pachymic,
  author = {Guilin Ren and Yiyou Lin and Jiannan Qiu and Xiao Han and Lin Chen and Linwensi Zhu and Xiaohui Fan and Xiaobing Dou and Qingsheng Liu},
  title = {{Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα}},
  booktitle = {Frontiers in Pharmacology},
  year = {2025},
  doi = {10.3389/fphar.2025.1554850},
}
Figure